CRISPR/Cas9-loaded cancer-derived EVs suppress expression of poly (ADP-ribose) polymerase-1 (PARP-1), enhance the chemical sensitivity of ovarian cancer cells to cisplatin and induce cell apoptosis (Kim et al., 2017). The gene discussed is PARP1; the disease is ovarian cancer.